The effect of tuning cold plasma composition on glioblastoma cell viability by Cheng, Xiaoqian et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Biochemistry and Molecular Medicine Faculty
Publications Biochemistry and Molecular Medicine
5-30-2014











USMI, Takoma Park, MD
See next page for additional authors
Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs
Part of the Biochemistry, Biophysics, and Structural Biology Commons
This Journal Article is brought to you for free and open access by the Biochemistry and Molecular Medicine at Health Sciences Research Commons. It
has been accepted for inclusion in Biochemistry and Molecular Medicine Faculty Publications by an authorized administrator of Health Sciences
Research Commons. For more information, please contact hsrc@gwu.edu.
Recommended Citation
Cheng, X., Sherman, J., Murphy, W., Ratovitski, E., Canady, J. et al. (2014). The effect of tuning cold plasma composition on
glioblastoma cell viability. PLoS ONE, 9(5), e98652.
Authors
Xiaoqian Cheng, Jonathan H. Sherman, William Murphy, Edward Ratovitski, Jerome Canady, and Michael
Keidar
This journal article is available at Health Sciences Research Commons: http://hsrc.himmelfarb.gwu.edu/smhs_biochem_facpubs/
131
The Effect of Tuning Cold Plasma Composition on
Glioblastoma Cell Viability
Xiaoqian Cheng1, Jonathan Sherman2, William Murphy3, Edward Ratovitski1,4, Jerome Canady5,
Michael Keidar1*
1Department of Mechanical and Aerospace Engineering, The George Washington University, Washington, D.C., United States of America, 2Department of Neurosurgery,
The George Washington University, Washington, D.C., United States of America, 3Department of Electrical and Computer Engineering, The George Washington University,
Washington, D.C., United States of America, 4Head and Neck Cancer Research Division, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
of America, 5 Institute for Advanced Biological and Technical Sciences, USMI, Takoma Park, Maryland, United States of America
Abstract
Previous research in cold atmospheric plasma (CAP) and cancer cell interaction has repeatedly proven that the cold plasma
induced cell death. It is postulated that the reactive oxygen species (ROS) and reactive nitrogen species (RNS) play a major
role in the CAP cancer therapy. In this paper, we seek to determine a mechanism of CAP therapy on glioblastoma cells (U87)
through an understanding of the composition of the plasma, including treatment time, voltage, flow-rate and plasma-gas
composition. In order to determine the threshold of plasma treatment on U87, normal human astrocytes (E6/E7) were used
as the comparison cell line. Our data showed that the 30 sec plasma treatment caused 3-fold cell death in the U87 cells
compared to the E6/E7 cells. All the other compositions of cold plasma were performed based on this result: plasma
treatment time was maintained at 30 s per well while other plasma characteristics such as voltage, flow rate of source gas,
and composition of source gas were changed one at a time to vary the intensity of the reactive species composition in the
plasma jet, which may finally have various effect on cells reflected by cell viability. We defined a term ‘‘plasma dosage’’ to
summarize the relationship of all the characteristics and cell viability.
Citation: Cheng X, Sherman J, Murphy W, Ratovitski E, Canady J, et al. (2014) The Effect of Tuning Cold Plasma Composition on Glioblastoma Cell Viability. PLoS
ONE 9(5): e98652. doi:10.1371/journal.pone.0098652
Editor: Mohammed Yousfi, University Paul Sabatier, France
Received January 24, 2014; Accepted May 6, 2014; Published May 30, 2014
Copyright:  2014 Cheng et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Support was provided by a Katzen Research Grant (http://www.katzencancer.org/index.php/research/). The funder had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: keidar@gwu.edu
Introduction
Recent development in physics research has lead to the
production of cold atmospheric pressure plasma, a type of plasma
that is formed at relatively ‘‘cold’’ temperatures, or room
temperature. Previously, plasma was limited in application by its
properties, including high voltage and high temperatures, but this
most recent innovation has moved the focus to possible biological
applications including food disinfection, wound healing, surgical
procedures and even cancer treatment [1][2]. The treatment of
living tissues by cold plasma can be classified into two approaches:
dielectric barrier discharge (DBD) and plasma jet. DBD is
generated at a high voltage between two electrodes in the air,
with at least one electrode being insulated in order to prevent
current build-up, creating electrically safe plasma without
substantial gas heating [3]. In the case of DBD, all the generated
agents have direct contact with the treated sample. Plasma jets, on
the other hand, also have high voltage between two electrodes,
generate plasma inside of a quartz tube [4] and treat biological
samples remotely. In this study, a helium plasma jet is employed
because it produces a stable, homogenous and uniform discharge
at atmospheric pressure, and it operates without a dielectric cover
over the electrode, yet is free from filaments, streamers and arcing
[5].
Cancer is a vast collection of diseases that share a common
devastating similarity of unrestricted cell growth, however
similarity in cell functions and metabolism between normal and
tumor tissues creates serious obstacles in the specific ablation of
tumor tissue, while leaving normal tissue intact and unharmed. To
improve efficiency and safety of anti-cancer therapies the
researchers and clinicians alike are prompted to develop targeted
combined therapies that especially minimize damage to healthy
tissues while eradicating the body of cancerous tissues.
In the recent decade, astounding phenomenon between both
cold plasma types and biological tissues has spurred a new era of
innovation in an emerging field called plasma medicine [2].
Various bacterial, such as Geobacillus stearothermophilus, bacillus
cereus, Escherichia coli [6][7], and mammalian cell types such as
neuroblastoma [8], pancreatic carcinoma [9][10], skin carcinoma
[11], lymphoblastic leukemia [12], hepatocellular carcinoma
[13][14][15], melanoma [16][17][18][19], cervical carcinoma
[20][21], lung carcinoma [22][23][24], bladder carcinoma [22],
colon carcinoma [17], breast cancer [25], have been utilized for
both in vitro and in vivo plasma therapy studies. Glioblastoma
multiforme (GBM) is the most common and aggressive malignant
primary brain tumor in humans, involving glial cells and
accounting for 52% of all functional tissue brain tumor cases
and 20% of all intracranial tumors. GBM is rare, with incidence of
2–3 cases per 100,000 individuals in Europe and North America
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[26]. The prognosis of this disease is generally no more than one
year and the long-term survival is small [26]. Attributed to its
multiformity and aggressiveness, this cancer is highly resistant to
treatments including chemotherapy, radiation therapy and surgery
[27]. Being the most common brain tumor [28], it garners much
interest by researchers to develop novel treatments and is used in
this paper as a model cell-line for treatment.
Previous research in cold atmospheric plasma (CAP) and cancer
cell interaction has repeatedly proven that there is a strong
connection between CAP therapy and cell death [8][12][22][29].
Reactive oxygen species and reactive nitrogen species (ROS/RNS)
were postulated to play a major mechanistic role in the CAP
cancer therapy [8]. Intracellular ROS/RNS have been shown at
low levels to induce a proliferate cell growth, whereas at high
levels, above a certain threshold, cause an apoptotic arrest in
cancer cells [30]. Plasma generated species (to distinguish them
from the intracellular ROS/RNS, they were described as
extracellular ROS/RNS) may be delivered into the cells directly
by the media, stimulating the cells to produce a massive amount of
intracellular ROS/RNS, or they react with the culture media to
form other reactive species. Either one or both of the two cases
generate great oxidative stress to cells, leading to cell death. The
mechanism for this exact interaction, however, is not fully
understood and not conclusively proven. The basic way to
understand the mechanism by which CAP exerts its effect on
tumor cells is to figure out the plasma jet composition. In this
study, a thorough understanding of how each species of the CAP
treatment impacts cell viability is provided. CM_H2DCFDA (Life
Figure 1. (a) The cold plasma device setup: voltage supply, control box, plasma head, and flow meter. (b) The extension tube was attached on the
nozzle to eliminate the sparks near the central electrode. Optical probe was placed in front of the extension at a distance of,2.5 cm, same as the real
treatment distance between the plasma nozzle and the cells (c) Schematic image of the CAP device.
doi:10.1371/journal.pone.0098652.g001
Figure 2. Typical spectrum of helium plasma jet (measured at
output of 3.16 kV and helium flow rate at 4.7 l/min). The
determination of major reactive species is shown.
doi:10.1371/journal.pone.0098652.g002
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Technologies), an indicator for reactive oxygen species in the cells,
was utilized to demonstrate how intracellular ROS level varies
with the different plasma composition (extracellular ROS/RNS
level). In order to determine the threshold of plasma treatment on
U87, normal human astrocytes (E6/E7) were used as the
comparison cell line. The CAP therapy is multifaceted in the
way it produces ‘‘plasma dosage’’ including treatment time,
voltage, flow-rate and plasma-gas composition. This study is
designed to determine a chemical mechanism of CAP therapy
through an understanding of the composition of the plasma and
conditions of its usage.
Materials and Methods
1. Cold Atmospheric Plasma Configuration
The cold plasma device created at the George Washington
University has a configuration of central powered electrode of
1 mm diameter and a grounded outer electrode wrapped around
the outside of a 4.5 mm diameter quartz tube (Figure 1). The
electrodes were connected to a secondary of high voltage resonant
transformer (voltage up to 10 kV, frequency ,30 kHz) [4]. The
plasma discharge was driven by AC high voltage. Electrical
measurements were performed with a Tektronix TDS3014C
Digital Phosphor Oscilloscope. Emission spectra were recorded
with an optical fiber which was connected to a fiber optic
spectrometer (EPP2000-HR, Stella Net, measurements can be
made in UV-VIS-NIR ranges from 190–2200 nm). The feeding
gas was helium and helium/oxygen mixture. In order to show the
combination impact of flow rate, gas content, output voltage,
incubation time after treatment, and treatment duration, cells were
placed into three 96-well plates. The helium flow rate was within
the range of 2,6 l/min; when the helium (He)/oxygen (O2)
mixture as the feeding gas, the oxygen percentage was 0 , 0.63%
(v/v). The output voltage was set to 3.16 kV.
Figure 3. (a) The increase in output voltage from 2.56 to 3.8 kV led to the corresponding rise in the intensity of each species. (b) A closer look at the
increasing trend of major ROS and RNS species with voltage increasing. (c) The increasing of each species is proportionally to the output voltage
increasing from 2.56 to 3.8 kV when normalized to He (706 nm).
doi:10.1371/journal.pone.0098652.g003
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2. Optical Emission Spectroscopy
In the present work, a range of wavelength 250–850 nm, i.e.
UV-visible-NIR, was investigated on CAP jet to detect various
ROS and RNS (atomic oxygen [O], hydroxyl radical [-OH], nitric
oxide [-NO], nitrogen [N2], and nitrogen cation [N2
+]). The
spectrometer and the detection probe were purchased from Stellar
Net Inc. Instead of pointing the probe directly to the nozzle of the
CAP jet, an extension tube was used to prolong the jet to eliminate
the emission of the discharge near the central electrode (Figure 1).
The discharge area produced was of great concern in spectro-
scopic studies of the plasma jet since it was located at a significant
distance from the treatment area. As such, a setup was devised to
minimize the measurement of the discharge area and solely focus
on the afterglow. Under normal treatment conditions, used in this
research, the afterglow was the area of most importance to study.
Figure 4. (a) 24, 48, 72 h MTT assay results of U87 treated with 5–60 s duration of helium plasma jet. (b) 24, 48, 72 h MTT assay results of E6/E7
treated with 5–60 s duration of helium plasma jet.
doi:10.1371/journal.pone.0098652.g004
Figure 5. (a) The spectrum of helium plasma jet with flow rate of 2.0, 4.7 and 6.34 l/min. (b) The trend of major RNS and ROS with helium flow rate
change at 2.0, 4.7, and 6.4 l/min.
doi:10.1371/journal.pone.0098652.g005
Cold Plasma Effect on Glioblastoma Cells
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Following this logic, an extension tube was created that had a
central electrode to guide the cold atmospheric pressure plasma
jet’s afterglow a distance away from the plasma jet to be studied.
This was far enough away from the discharge so as not to factor in
the excess electromagnetic radiation produced. Per experimental
design, the fiber optical spectrometric device was parallel to the
extended jet and in directly in line with the afterglow. This is the
most logic measurement approach, since the cells are treated
directly under the jet. The extension tube was sealed tightly
around the discharge area of the tube. A secondary central
electrode was used to propagate the plasma afterglow a sustainable
distance away from the discharge area. The plasma afterglow was
measured in line-of-sight of the jet by the fiber optical
spectrophotometric device. The optical probe was place at a
distance of ,2.5 cm in front of the extension tube, coherent with
the real distance between the plasma jet nozzle and the cells
during treatment. This is a critical precision because the spectrum
of the jet will vary with the specific measure point, and the content
of ambient air such as N2, O2 and H2O will affect the intensity of
oxygen, nitrogen, and hydroxyl radicals [31][32]. Integration time
of the collecting data was set to 100 ms.
3. Cell Culture
The human brain glioblastoma cancer cell line, U87, and the
normal human astrocytes, E6/E7, were used in this study. Both
cell lines were cultured in Dulbecco’s Modified Eagle Medium
(Life Technologies) supplemented with 10% (v/v) fetal bovine
serum (Atlantic Biologicals) and 1% (v/v) Penicillin and Strepto-
mycin (Life Technologies). Cultures were maintained at 37uC in a
humidified incubator containing 5% (v/v) CO2. Cells were
observed under a Nikon Eclipse TS100 inverted microscope.
4. Cell Viability Assay
Cell viability was monitored using the MTT assay (Sigma-
Aldrich, M2128), which is a colorimetric assay for measuring the
activity of mitochondria and cellular dehydrogenase enzymes that
reduce 3-[4, 5-dimethylthiazol-2-yl]-2, 5-dyphenyltetrazolium
bromide, MTT, to its insoluble formazan, giving a purple color.
Cells were plated into three 96-well flat-bottomed microplates
(Falcon) in 100 ul medium per well. Confluence of each well was
ensured to be at ,15–20%. Cells were then incubated for one day
to ensure a proper cell adherence and stability. Cells were rinsed
with phosphate buffered saline (PBS) replaced with a fresh
medium, and treated with CAP followed by an additional
incubation at 37 C for 24, 48, and 72 h. Cells were then rinsed
with PBS, and 100 ul of MTT solution per well (7 mg Thiazolyl
Blue Tetrazolium Blue in 10 ml medium for one plate) was added
into each well. Reactions were maintained for 3 h at 37uC. The
MTT solution was aspirated and 100 ul of MTT solvent (0.4% (v/
v) HCl in anhydrous isopropanol) was added to each well to
dissolve formazan crystals. Reactions were monitored by the
Synergy H1 Hybrid Multi-Mode Microplate Reader at 570 nm.
Each one of the conditions (voltage, flow rate, oxygen fraction,
treatment time, and incubation time after treatment) was applied
to 12 wells in one trial. The entire set of experiments was repeated
three times in triplicate. This made the sample size 36.
5. Intracellular ROS (General) Measurement and
Peroxynitrite Measurement
5, 6-Chloromethyl-29, 79-dichlorodihydrofluorescein diacetate
(CM-H2DCFDA) was purchased from Invitrogen for the general
intracellular ROS measurement. U87 cells were plated in 35 mm
glass bottom culture dishes (MatTek Corporation). Detailed
protocol can be found on the Invitrogen website. Briefly, 24 h
after the plating, the medium was aspirated, and CM-H2DCFDA
solution (8.5 nM) was added. Afterwards, the cells were treated
with helium cold plasma under various conditions. 30 min later,
fluorescence images were obtained by the Laser Scanning
Confocal microscopy (LSCM, Zeiss, LSM 510) at 40x magnifica-
tion. For images with CM-H2DCFDA, an excitation wavelength
of 488 nm and emission wavelength of 515 nm were used.
Quantification of the fluorescence intensities was performed by the
official software Zen 2012 lite.
Peroxynitrite (ONOO-) detection kit was purchased from Cell
Technology. The experiment was performed exactly according to
the detailed protocols given on the official website. Cells were
plated in black clear-bottom 96 well plates (purchased from
Costar). The final solution of the dye added into the cells was
5 nM. After loaded with the dye, the cells were treated with
plasma under various helium flow rate. The fluorescence intensity
of the ONOO- was obtained with a microplate reader (Synergy
H1 Hybrid Multi-Mode) 1 h after the plasma treatment.
6. Statistical Analysis
Results were plotted using a Microsoft Excel software (2010 for
Windows) as mean 6 standard deviation. Student t-test was used
to check the statistical significance (*p,0.05, **p,0.01, ***p,
0.001).
Figure 6. 24, 48, 72 h MTT assay results of U87 treated with
2.0–6.34 l/min helium flow rate.
doi:10.1371/journal.pone.0098652.g006
Figure 7. Intracellular peroxynitrite intensity measured in U87
after plasma treatment with various helium flow rate. Measure-
ment was performed at 1 h time point post-plasma treatment.
doi:10.1371/journal.pone.0098652.g007
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Results and Discussion
Figure 2 shows a typical spectrum of helium cold plasma jet
interacting with the ambient air with output voltage of 3.16 kV
and a helium flow rate of 4.7 l/min. The identification of emission
lines and bands was mainly according to [33]. In the special range
of 250–300 nm, there are very weak emission lines, which are
detected as NO lines [34]. Their magnitudes are at most a few
thousandths of the highest peak N2
+ (391 nm). Repeated
measurements (data not shown) were performed to confirm the
result. As previously shown, the inactivation effect on bacteria by
UV-radiation is mostly related to the DNA/RNA damage in UV
wavelength of 200–280 nm [35]. Thus, it can be concluded that
UV photons are not major CAP species with the experimental
setup. The features were assigned as helium (He) lines between
550–750 nm.
Atomic oxygen (O) (including the ground state and all the
excited states of atomic oxygen) is believed to have a significant
effect on cells and therefore a broad biomedical application. The
species lines between 300–500 nm are still not clearly determined
[34][36]. Species at the wavelengths of 316, 337, 358 nm could be
defined as N2
3P or NO b 2P (denoted as N2/NO in the following
text) according to [33], because both of the two species have
possible optical emission at these wavelengths. The cold plasma jet
is a complicated environment that combines the comprehensive
effect of different ions and neutrals. It is shown that O (777 nm),
OH (309 nm), N2
+ (391 nm), N2 or NO lines (316, 337, 358,
427.5 nm) are the domain species of the spectra.
1. Voltage Variation Effect
The increase in output voltage from 2.56 to 3.8 kV led to the
corresponding rise in the intensity of each species (Figure 3a).
Figure 3b gives a closer look at the increasing trend of major ROS
and RNS species. Helium line at 706 nm is known to represent
energetic electrons [37], and recently it has been linked to
energetic electrons in RF atmospheric plasmas [38][39]. Hence,
the intensities of the major species were normalized to He
(706 nm), shown in Figure 3c. The flat lines demonstrate that the
increasing of each species is proportionally to the output voltage
increasing from 2.56 to 3.8 kV.
2. Plasma Treatment Duration Effect
A. Cell viability. To find out the duration time needed for
helium plasma therapy of U87 cells, the normal human astrocytes
E6/E7 were used as contrast cell line. Both cancer and normal
cells were treated for various durations from 5 sec to 60 sec. The
results of the MTT assay (Figure 4) showed that after 72 h, around
80% of U87 cells died at 30 sec and 60 sec of plasma treatment,
while E6/E7 cells remained 90% and 60% cell viability at 30 sec
and 60 sec plasma treatment at 72 h post-treatment time point.
The p values for both cell lines after 60 sec treatment after 72 h
showed statistically significant compared to control, while the p
value for 30 sec plasma treated E6/E7 was not (Figure 4). So the
threshold needed for U87 cells is determined as 30 sec. Normally a
LD50 (median lethal dose) data should be presented to determine a
threshold of a drug or a physical agent, but in this special case,
normal cells remained their viability above 50%, while viability of
30s- and 60s- plasma treated U87 cells dropped below 50% less
than 48 h (Figure 4). All MTT assays of the other characterization
of plasma composition (source gas flow rate, source gas
composition) were based on this threshold: plasma treatment
duration was kept at 30 sec per well.
3. Helium Flow Rate Variation Effect
A. On spectrum. Three values of helium flow rate were
chosen to treat the U87 cells: 3.15, 4.70, 6.34 l/min, while the
output voltage was kept at 3.16 kV. The trend of major ROS and
RNS increasing with helium flow rate were depicted in Figure 5a.
We showed that the main increase occurred at the wavelength of
300,500 nm, namely, RNS (Figure 2). Figure 5b more intuitively
Figure 8. (a) Comparison between spectrum of He/O2 mixture plasma jet and He plasma jet at output voltage 3.16 kV. (b) The trend of major plasma
generated RNS and ROS with oxygen volume fraction change at 0, 0.21, 0.42, 0.63%.
doi:10.1371/journal.pone.0098652.g008
Figure 9. 24, 48, 72 h MTT assay results of U87 treated with 0–
0.63% oxygen fractions in the He/O2 mixture gas.
doi:10.1371/journal.pone.0098652.g009
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demonstrated that the NO/N2 (337 nm, green), NO/N2 (358 nm,
purple), and N2
+ (391 nm, blue) increased faster than OH
(309 nm, orange) and O (777 nm, red).
B. On cell viability. The same setup and conditions of
various helium flow rate plasma as used in spectrum measurement
were used on U87 cells cultured in 96 well plates, as described in
Materials and Methods section. Each well was treated for 30 s.
The results from the MTT assay showing the effect of helium flow
rate on the cell viability were depicted in Figure 6. The MTT
assays were performed at 24, 48, 72 h after treatment under
different conditions. All cell viability data were normalized relative
to control. Figure 5 and 6 demonstrated that the higher the helium
flow rate is, the higher ratio of RNS/ROS was observed, and the
cell viability decreased. This suggests that RNS generated
exogenously by the CAP device more significantly contribute to
the survival of U87 cancer cells under the CAP treatment than
exogenous ROS.
It is well-known that NO is an omnipresent intercellular
messenger in all vertebrates, modulating blood flow, thrombosis,
neuronal activity, immune response, inflammation, and plays a
critical role in tumorigenesis by modulating the apoptotic
machinery [13][14][15][16]. According to Pacher and co-workers,
NO and superoxide (O2
2) can easily form peroxynitrite
(ONOO2) once they collide or even locate within a few cell
diameters of each other [40]. Peroxynitrite is a powerful oxidant
and nitrating agent that is known to be a much more damaging to
the cells than NO or superoxide, because cells readily remove
superoxide and NO to reduce their harmful effects, while fail to
neutralize peroxynitrite [41]. A major limitation to the acceptance
of peroxynitrite or any RNS as a significant player in disease was
whether enough could be produced to exert a sufficient damage to
tumor cells. To test this notion, we used spectral imaging showing
that CAP with helium gas produced both RNS and ROS
exogenously, with the former appear in higher concentrations
(Figure 5). This is the perfect condition for peroxynitrite formation
when directly applied to a cellular environment. As shown in
Figure 7, the intensity of ONOO- increases with helium flow rate.
The measurement of ONOO- was performed at 1 h time point
after the helium plasma treatment with various flow rate. The rate
for peroxynitrite synthesis increases drastically with a modest
increase of the simultaneous production of superoxide and NO.
According to Lukes et al, the formation of NO2?, NO? and OH?
radicals and NO+ ions by the discharge of plasma are at the gas-
liquid interface and in the liquid [42]. Consequently, the
generation of a moderate flux of peroxynitrite over long periods
of time would result in substantial oxidation and potential
destruction of host cellular components leading to a deregulation
of critical cellular processes, disruption of cell signaling pathways,
and induction of the cell death through both apoptosis and
Figure 10. (a) Intracellular ROS generation in U87 cells under 0–60 s plasma treatment durations. Images were taken 30 min after the plasma
treatment. (b) Quantification of the ROS intensity with Zen 2012 Lite.
doi:10.1371/journal.pone.0098652.g010
Figure 11. Dependence of cell viability dependence on
‘‘plasma dosage’’ (dash line: E6/E7 cell viability trendline of
24, 48, 72 h incubation after plasma treatment; solid line: U87
viability trendline of 24, 48, 72 h incubation after plasma
treatment).
doi:10.1371/journal.pone.0098652.g011
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necrosis [43]. This can be an explanation why the cell viability did
not drop much during the first 24 h after the CAP treatment,
however decreased dramatically after 72 h (Figure 6).
4. Oxygen Fraction Effect
A. On spectrum. Figure 8 shows the volume fraction of
oxygen’s impact on the spectrum of the mixture plasma jet. The
experimental setup was chosen as 0.21%, 0.42%, and 0.63% for
oxygen fraction in the mixture gas, while the other conditions were
kept the same (He flow rate remained at 4.7 l/min; output voltage
remained at 3.16 kV). The addition of oxygen into the plasma gas
supply makes the ionization extremely difficult. The plasma plume
dampened very quickly even with a tiny bit of oxygen fraction
increase. As shown in Figures 8a and 8b, the addition of a small
amount of oxygen (from 0% to 0.21%) resulted in a rapid damp of
the jet, especially the species in the range of 300,450 nm, while
RNS almost disappeared in mixture gas plasma (blue) compared to
helium gas plasma (red). Although the intensity of every species
decreased significantly with the addition of oxygen, the latter was
the only species that increased (Figure 8b). With more oxygen
added (from 0.21% to 0.42% and 0.63%), every species decreased
at the same rate.
B. Cell viability. We next tested the effect of oxygen volume
fraction on the cell viability. The conditions used for cell treatment
were exactly the same as described above in He/O2 mixture gas
spectrum. The MTT assays were performed at 24, 48, 72 h after
treatment. All viability data were normalized relative to control.
Using MTT assay, we showed that the addition of oxygen into the
gas supply weakened the therapeutic effect of cold plasma on the
cancer cells (Figure 9). As shown in Figure 9, the cell viability
increased over 60% after 72 h compared to 30% when cells were
treated with the helium gas plasma jet. Along with the data
presented in Figure 8 showing that every species was dampened by
oxygen addition except O at 777 nm, the results of cell viability
assays (Figure 9) suggest that the admixture of even the slightest
amount of oxygen decreases the intensity of the cold atmospheric
plasma jet, which decreased the produciton of peroxynitrite as
discussed above and therefore decrease the cell death rate.
5. Intracellular ROS Measurement
Using the CM_H2DCFDA redox probe and confocal imaging,
we next measured the intracellular ROS generation in U87 cells
treated for various durations. The probe is non-fluorescent when
chemically reduced, but after cellular oxidation and removal of
acetate groups by cellular esterases the redox probe becomes
fluorescent. As shown in Figure 10a, the left image section presents
the fluorescent production within the cells, while the right section
is the natural white channel (scale bar 50 mm). Figure 10b
demonstrates the mean intensity of fluorescence as a function of
plasma treatment duration. These data indicate that the longer
plasma treatment was, the more amount of ROS the cells
produced. But the mechanism of the ROS production, whether
ROS is generated by the cold plasma jet and then directly
penetrated into the cells, or the cold plasma stimulated the cells to
induce the corresponding enzymes and produce endogenous ROS
at a higher ratio, is not yet understood.
CAP Dose
In summary, we varied the characteristics of the cold plasma
(treatment duration, input/output voltage, flow rate and compo-
sition of feed gas) in order to obtain different major species. From
the above results, we use ‘‘plasma dosage’’ to summarize all the
variables, i.e.
D*Q  V  t,
where D is the entire ‘‘plasma dosage’’ applied to the cells; Q is the
flow rate of the feeding gas (helium); V is the output voltage; t is the
treatment time.
These various conditions were applied on glioblastoma U87
cells to achieve the corresponding/desirable cell death rate. To
relate the cell viability to the variables, we could conclude that the
higher ‘‘plasma dosage’’, the more the cell viability decreased, as
showed in Figure 11.
The above formula for ‘‘plasma dosage’’ summarized from the
above experiments is exclusively applicable for our helium plasma
jet. When it comes to oxygen and helium mixture gas, the
ionization gets more complicated, and the intensity of the plasma
jet is significantly reduced. Because of that complexity, it is difficult
to determine whether atomic oxygen generated by the mixture
plasma gas protects the cells or the RNS are dampened so that less
peroxinitrite was produced to create oxidative stress on the cells.
More experiments on the effects of specific ROS (O2
2, O3) and
RNS (NO, N2
+) needed to be performed to more clearly
understand the production of each species by CAP and confirm
the hypothesis underlying the peroxynitrite effect on cell viability.
Summary
It should be acknowledged that the major factors in plasma
dosage are the gas flow rate, output voltage difference at the
electrodes and the duration of exposure to the plasma. These three
components cause a respective decrease in cell viability for cancer
cells. The mechanism for which cold atmospheric pressure plasma
kills cancer cells, through measurements of reactive oxygen
species, can be conclusively stated to be in part by these factors.
The relationship between these factors and species production is
understood by the spectral measurements conducted. Each part
plays a role in creating larger concentrations of reactive species:
the voltage by increasing the rate of ionization, the duration by
increasing the number of species that come in contact with the
cancer cells and flow rate which creates a gaseous volume that
facilitates better ionization. Data has already shown that
increasing reactive species endogenously past a certain threshold
results in apoptosis and necrosis, so increasing the ‘‘plasma
dosage’’ results in higher exogenous reactive species which in turn
increase endogenous concentrations through cellular uptake.
Acknowledgments
The authors would like to thank the Center for Microscopy and Image
Analysis (CMIA) at The George Washington University for the imaging
support and the manager Dr. Anastas Popratiloff for his valuable
instruction and advice. The human brain glioblastoma cancer cell line,
U87, was kindly provided by Dr. Ferid Murad’s lab from the Department
of Biochemistry and Molecular Biology at the GWU. The normal human
astrocytes, E6/E7, were generously donated by Dr. Russell Pieper at The
University of California San Francisco [44].
Author Contributions
Conceived and designed the experiments: XC MK. Performed the
experiments: XC WM. Analyzed the data: XC. Contributed reagents/
materials/analysis tools: JS MK JC. Wrote the paper: XC WM ER.
Cold Plasma Effect on Glioblastoma Cells
PLOS ONE | www.plosone.org 8 May 2014 | Volume 9 | Issue 5 | e98652
References
1. Keidar M, Isak Beilis (2013) Plasma Engineering: Application in Aerospace,
Nanotechnology and Bionanotechnology. 1st ed. Elsevier BV.
2. Yousfi M, Merbahi N, Pathak A, Eichwald O (2014) Low-temperature plasmas
at atmospheric pressure: toward new pharmaceutical treatments in medicine.
Fundam Clin Pharmacol 28: 123–135.
3. Kalghatgi S, Kelly CM, Cerchar E, Torabi B, Alekseev O, et al. (2011) Effects of
non-thermal plasma on mammalian cells. PLoS One 6: e16270.
4. Shashurin A, Keidar M, Bronnikov S, Jurjus RA, Stepp MA (2008) Living tissue
under treatment of cold plasma atmospheric jet. Appl Phys Lett 93: 181501.
5. Nehra V, Kumar A, Dwivedi H (2008) Atmospheric non-thermal plasma
sources. Int J Eng 2: 53–68.
6. Morris AD, McCombs GB, Akan T, Hynes W, Laroussi M, et al. (2009) Cold
Plasma Technology: Bactericidal Effects on Geobacillus Stearothermophilus and
Bacillus Cereus Microorganisms. J Dent Hyg 83: 55–61.
7. Ziuzina D, Patil S, Cullen PJ, Keener KM, Bourke P (2013) Atmospheric cold
plasma inactivation of Escherichia coli in liquid media inside a sealed package.
J Appl Microbiol 114: 778–787.
8. Walk RM, Snyder JA, Srinivasan P, Kirsch J, Diaz SO, et al. (2013) Cold
atmospheric plasma for the ablative treatment of neuroblastoma. J Pediatr Surg
48: 67–73.
9. Brulle´ L, Vandamme M, Rie`s D, Martel E, Robert E, et al. (2012) Effects of a
non thermal plasma treatment alone or in combination with gemcitabine in a
MIA PaCa2-luc orthotopic pancreatic carcinoma model. PLoS One 7: e52653.
10. Partecke LI, Evert K, Haugk J, Doering F, Normann L, et al. (2012) Tissue
tolerable plasma (TTP) induces apoptosis in pancreatic cancer cells in vitro and
in vivo. BMC Cancer 12: 473.
11. Volotskova O, Hawley TS, Stepp MA, Keidar M (2012) Targeting the cancer
cell cycle by cold atmospheric plasma. Sci Rep 2: 636.
12. Barekzi N, Laroussi M (2012) Dose-dependent killing of leukemia cells by low-
temperature plasma. J Phys D Appl Phys 45: 422002.
13. Yan X, Xiong Z, Zou F, Zhao S, Lu X, et al. (2012) Plasma-Induced Death of
HepG2 Cancer Cells: Intracellular Effects of Reactive Species. Plasma Process
Polym 9: 59–66.
14. Zhang X, Li M, Zhou R, Feng K, Yang S (2008) Ablation of liver cancer cells
in vitro by a plasma needle. Appl Phys Lett 93: 021502.
15. Yonson S, Coulombe S, Le´veille´ V, Leask RL (2006) Cell treatment and surface
functionalization using a miniature atmospheric pressure glow discharge plasma
torch. J Phys D Appl Phys 39: 3508–3513.
16. Zucker SN, Zirnheld J, Bagati A, Disanto TM, Soye B Des, et al. (2012)
Preferential induction of apoptotic cell death in melanoma cells as compared
with normal keratinocytes using a non-thermal plasma torch. Cancer Biol Ther
13: 1299–1306.
17. Georgescu N, Lupu AR (2010) Tumoral and Normal Cells Treatment With
High-Voltage Pulsed Cold Atmospheric Plasma Jets. IEEE Trans Plasma Sci 38:
1949–1955.
18. Zirnheld JL, Zucker SN, DiSanto TM, Berezney R, Etemadi K (2010)
Nonthermal Plasma Needle: Development and Targeting of Melanoma Cells.
IEEE Trans Plasma Sci 38: 948–952.
19. Lee HJ, Shon CH, Kim YS, Kim S, Kim GC, et al. (2009) Degradation of
adhesion molecules of G361 melanoma cells by a non-thermal atmospheric
pressure microplasma. New J Phys 11: 115026.
20. Ahn HJ, Kim K Il, Kim G, Moon E, Yang SS, et al. (2011) Atmospheric-
pressure plasma jet induces apoptosis involving mitochondria via generation of
free radicals. PLoS One 6: e28154.
21. Leduc M, Guay D, Leask RL, Coulombe S (2009) Cell permeabilization using a
non-thermal plasma. New J Phys 11: 115021.
22. Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, et al. (2011) Cold
plasma selectivity and the possibility of a paradigm shift in cancer therapy.
Br J Cancer 105: 1295–1301.
23. Kim JY, Ballato J, Foy P, Hawkins T, Wei Y, et al. (2011) Apoptosis of lung
carcinoma cells induced by a flexible optical fiber-based cold microplasma.
Biosens Bioelectron 28: 333–338.
24. Stoffels E, Kieft IE, Sladek REJ, Bedem LJM Van Den, Laan EP Van Der, et al.
(2006) Plasma needle for in vivo medical treatment: recent developments and
perspectives. Plasma Sources Sci Technol 15: S169–S180.
25. Kim SJ, Chung TH, Bae SH, Leem SH (2010) Induction of apoptosis in human
breast cancer cells by a pulsed atmospheric pressure plasma jet. Appl Phys Lett
97: 023702.
26. Johnson DR, O’Neill BP (2012) Glioblastoma survival in the United States
before and during the temozolomide era. J Neurooncol 107: 359–364.
27. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, et al. (2008) Stem cell-
related ‘‘self-renewal’’ signature and high epidermal growth factor receptor
expression associated with resistance to concomitant chemoradiotherapy in
glioblastoma. J Clin Oncol 26: 3015–3024.
28. Ohgaki H (2009) Epidemiology of Brain Tumors. Methods Mol Biol 472: 323–
342.
29. Keidar M, Shashurin A, Volotskova O, Ann Stepp M, Srinivasan P, et al. (2013)
Cold atmospheric plasma in cancer therapy. Phys Plasmas 20: 057101.
30. Gupta SC, Hevia D, Patchva S, Park B, Koh W, et al. (2012) Upsides and
downsides of reactive oxygen species for cancer: the roles of reactive oxygen
species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 16:
1295–1322.
31. Du¨nnbier M, Schmidt-Bleker A, Winter J, Wolfram M, Hippler R, et al. (2013)
Ambient air particle transport into the effluent of a cold atmospheric-pressure
argon plasma jet investigated by molecular beam mass spectrometry.
J Phys D Appl Phys 46: 435203.
32. Winter J, Wende K, Masur K, Iseni S, Du¨nnbier M, et al. (2013) Feed gas
humidity: a vital parameter affecting a cold atmospheric-pressure plasma jet and
plasma-treated human skin cells. J Phys D Appl Phys 46: 295401.
33. Pearse RWB, Gaydon AG (1976) The identification of molecular spectra. 4th ed.
Wiley.
34. Walsh JL, Kong MG (2008) Contrasting characteristics of linear-field and cross-
field atmospheric plasma jets. Appl Phys Lett 93: 111501.
35. Chen W, Huang J, Du N, Liu X-D, Wang X-Q, et al. (2012) Treatment of
enterococcus faecalis bacteria by a helium atmospheric cold plasma brush with
oxygen addition. J Appl Phys 112: 013304.
36. Chen W, Huang J, Du N, Liu X-D, Wang X-Q, et al. (2012) Treatment of
enterococcus faecalis bacteria by a helium atmospheric cold plasma brush with
oxygen addition. J Appl Phys 112: 013304.
37. Nersisyan G, Graham WG (2004) Characterization of a dielectric barrier
discharge operating in an open reactor with flowing helium. Plasma Sources Sci
Technol 13: 582–587.
38. Liu DW, Iza F, Kong MG (2009) Electron avalanches and diffused c-mode in
radio-frequency capacitively coupled atmospheric-pressure microplasmas. Appl
Phys Lett 95: 031501.
39. Nie Q, Cao Z, Ren CS, Wang DZ, Kong MG (2009) A two-dimensional cold
atmospheric plasma jet array for uniform treatment of large-area surfaces for
plasma medicine. New J Phys 11: 115015.
40. Pacher P, Beckman J, Liaudet L (2007) Nitric oxide and peroxynitrite in health
and disease. Physiol Rev 87: 315–424.
41. Beckman J, Koppenol W (1996) Nitric oxide, superoxide, and peroxynitrite: the
good, the bad, and the ugly. Am J Physiol Soc.
42. Lukes P, Dolezalova E, Sisrova I, Clupek M (2014) Aqueous-phase chemistry
and bactericidal effects from an air discharge plasma in contact with water:
evidence for the formation of peroxynitrite through a pseudo-second-order post-
discharge reaction of H 2 O 2 and HNO 2. Plasma Sources Sci Technol 23:
015019.
43. Vira´g L, Szabo´ E´, Gergely P, Szabo´ C (2003) Peroxynitrite-induced cytotoxicity:
mechanism and opportunities for intervention. Toxicol Lett 140–141: 113–124.
44. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, et al. (2007) Loss of
tumor suppressor PTEN function increases B7-H1 expression and immunore-
sistance in glioma. Nat Med 13: 84–88.
Cold Plasma Effect on Glioblastoma Cells
PLOS ONE | www.plosone.org 9 May 2014 | Volume 9 | Issue 5 | e98652
